Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results

      - Reports Full-Year Adjusted EPS of $4.29, Up 29.2 Percent; GAAP EPS of $3.13

      - Delivers Full-Year Adjusted Net Revenues of $22.819 Billion, Up 22.1 Percent on an Operational Basis; GAAP Net Revenues of $22.859 Billion, Up 14.5 Percent

      - Expanded Adjusted Operating Margin to 42.3 Percent in 2015, Up 610 Basis Points; Adjusted Gross Margin of 82.9 Percent, Up 280 Basis Points

      - Reports Fourth-Quarter Adjusted EPS of $1.13, Up 27 Percent; GAAP EPS of $0.92

      - Reports Fourth-Quarter Adjusted Net Revenues of $6.360 Billion, Up 24.4 Percent on an Operational Basis; GAAP Net Revenues of $6.40 Billion, Up 17.4 Percent

      - Revenue Growth in the Quarter Reflects 16.0 Percent Global Operational Sales Growth from HUMIRA; Reported Global HUMIRA Sales Increased 10.5 Percent

      - Fourth-Quarter Global IMBRUVICA Net Revenue was $343 Million; Fourth-Quarter Global VIEKIRA Sales were $554 Million

      - Confirms 2016 Adjusted EPS Guidance Range of $4.90 to $5.10, Reflecting Strong Double-Digit Growth Versus 2015


      News provided by

      AbbVie

      Jan 29, 2016, 07:47 ET

      Share this article

      Share this article


      NORTH CHICAGO, Ill., Jan. 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2015.

      "AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projections for the year," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance."

      Fourth-Quarter Results

      • Worldwide adjusted net revenues were $6.360 billion in the fourth-quarter, up 18.4 percent. On an operational basis, adjusted net revenues increased 24.4 percent, excluding a 6.0 percent unfavorable impact from foreign exchange rate fluctuations.
      • Global HUMIRA sales increased 16.0 percent on an operational basis, excluding the impact of foreign exchange. Exceptional U.S. HUMIRA growth of 20.7 percent was driven by continued momentum across all three major market categories - rheumatology, dermatology and gastroenterology. International HUMIRA sales growth was also strong in the fourth quarter, up 9.7 percent on an operational basis. Reported international HUMIRA sales growth in the quarter was reduced by 13.1 percent due to unfavorable foreign exchange.
      • Fourth-quarter global IMBRUVICA net revenue was $343 million, with U.S. sales of $295 million and international profit sharing of $48 million for the quarter.
      • Total company revenue growth was also driven by $554 million in global VIEKIRA sales in the quarter, as well as strong operational growth from Duodopa, Creon and Lupron.
      • Adjusted gross margin ratio in the fourth quarter was 80.5 percent, excluding intangible asset amortization and other specified items. On a GAAP basis, the gross margin ratio was 77.0 percent.
      • Adjusted selling, general and administrative (SG&A) expense was 23.9 percent of net revenues in the fourth quarter. On a GAAP basis, SG&A was 27.1 percent of net revenues.
      • Adjusted research and development (R&D) expense was 15.9 percent of net revenues in the quarter, reflecting funding actions in support of our mid- and late-stage pipeline. On a GAAP basis, R&D was 16.8 percent of net revenues.
      • Adjusted operating margin in the fourth quarter was 40.1 percent, compared to 35.8 percent in fourth-quarter 2014. On a GAAP basis, the operating margin was 33.0 percent.
      • Net interest expense was $199 million. The adjusted tax rate in the quarter was 21.6 percent and 21.1 percent on a GAAP basis.
      • Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $1.13 in the fourth quarter, up 27 percent. Diluted earnings per share were $0.92 on a GAAP basis.

      Key Events from the Fourth Quarter

      • AbbVie submitted a supplemental New Drug Application (sNDA) for ibrutinib (IMBRUVICA®) to the U.S. Food and Drug Administration (FDA) for use in treatment-naïve chronic lymphocytic leukemia (CLL) patients, based on results from the Phase 3 RESONATE™-2 study. These data, published in The New England Journal of Medicine (NEJM), found that IMBRUVICA significantly decreased the risk of progression or death (progression-free survival, PFS) and significantly decreased the risk of death (overall survival, OS) versus chlorambucil in treatment-naïve patients 65 years and older with CLL.
      • AbbVie submitted a New Drug Application (NDA) and a Marketing Authorization Application (MAA) for venetoclax in patients with relapsed/refractory (R/R) CLL in patients with chromosome 17p deletion to the FDA and European Medicines Agency (EMA), respectively. Priority review status was granted by the FDA and validation provided by the EMA for these submissions based on results from a Phase 2, open-label trial that found treatment with venetoclax demonstrated a 79.4 percent overall response rate (ORR) as monotherapy treatment, including patients that achieved complete remission.
      • AbbVie has now received three FDA Breakthrough Therapy Designations for venetoclax. The first designation was received early last year for the treatment of patients with R/R CLL with chromosome 17p deletion. The second designation for venetoclax was received earlier this month for combination therapy with rituximab for patients with R/R CLL, including those with chromosome 17p deletion. A third designation was received this week for venetoclax in combination with hypomethylating agents (HMAs) in patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy).
      • AbbVie submitted a sNDA to the FDA for labeling considerations based on safety and efficacy results from the Phase 3 HELIOS trial of IMBRUVICA in patients with R/R CLL. The trial found that treatment with IMBRUVICA plus bendamustine and rituximab, versus placebo plus rituximab, significantly reduced the risk of disease progression or death by 80 percent and significantly improved ORR compared to placebo plus rituximab in previously-treated CLL/SLL patients.
      • The FDA accepted AbbVie's sNDA and granted priority review for VIEKIRA PAK without ribavirin in patients with genotype 1b (GT1b) chronic hepatitis C virus infection (HCV) and compensated cirrhosis (Child-Pugh A). The application was supported by data from the TURQUOISE-III study, which showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR12) in this patient population.
      • AbbVie announced that the FDA accepted its NDA for a once-daily, fixed-dosed formulation of VIEKIRA PAK to treat GT1 HCV. The proposed dosing for the fixed-dose formulation is three oral tablets, taken once daily with a meal, with or without ribavirin. AbbVie anticipates regulatory action on the new formulation in 2016.
      • At the American Society of Hematology's Annual Meeting (ASH) in December 2015, AbbVie presented new results from a Phase 2, open-label study of venetoclax in treatment-naïve patients 65 years and older with AML who were not eligible for intensive-induction chemotherapy. These data found that combination treatment with venetoclax and hypomethylating agents resulted in complete response rates of approximately 71 percent, which is roughly double the response rate that would be expected with current standard of care treatment. AbbVie plans to initiate registration studies of venetoclax for this indication in 2016.
      • AbbVie's IMBRUVICA partner Janssen presented results from the Phase 3 RAY study which demonstrated treatment with IMBRUVICA significantly prolonged PFS and improved ORR in patients with R/R mantle-cell lymphoma (MCL), compared with temsirolimus. Specifically, IMBRUVICA was found to reduce the risk of disease progression or death by 57 percent with a median follow-up of 20 months. These data were also published online in The Lancet.
      • AbbVie announced that data from a Phase 2 study evaluating IMBRUVICA therapy in treatment-naïve patients with follicular lymphoma (FL) demonstrated that a combination of IMBRUVICA and rituximab was well-tolerated and associated with ORR of 82 percent.
      • AbbVie presented data from its next-generation HCV regimen (ABT-493 and ABT-530) being evaluated as a pan-genotypic, once-daily treatment option for patients with HCV at the 2015 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Results demonstrated 12 weeks of treatment resulted in 97-100 percent SVR12 in GT1 non-cirrhotic HCV, 96-100 percent in genotype (GT2) and 83-94 percent in genotype 3 (GT3) patients. Additionally, data from the SURVEYOR-I study were also presented at the meeting and showed that non-cirrhotic GT1 HCV patients who received shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved SVR12 rates of 97 percent. The company initiated Phase 3 studies in the fourth quarter of 2015.
      • At the American College of Rheumatology (ACR) Annual Meeting, AbbVie presented the full 12-week, Phase 2b safety data for ABT-494, an investigational oral JAK-1 inhibitor, from the BALANCE-I study (efficacy data was previously top-lined). This study evaluated a broad dose range to understand the boundaries of JAK-1 selectivity and the efficacy of ABT-494 versus placebo in previously treated patients with rheumatoid arthritis (RA) with persistent and active disease. The study met its primary endpoint, achieving an ACR20 response after 12 weeks of treatment using an LOCF approach, and ACR20 for all dose levels. The BALANCE I and II results support the company's decision to move ABT-494 into Phase 3 studies with a once-daily dose. The Phase 3 program was initiated in late 2015 and a Phase 2 trial of ABT-494 is ongoing for the treatment of Crohn's disease.
      • The FDA approved Empliciti (elotuzumab) for the treatment of multiple myeloma (MM) as a combination therapy in patients who have received one to three prior therapies. Empliciti was co-developed by AbbVie and Bristol-Myers Squibb (BMS) and will be marketed by BMS. This approval was based on data from a Phase 3 study which demonstrated that patients treated with Empliciti plus standard of care therapy achieved a 30 percent reduction in the risk of disease progression or death compared to standard of care alone. This is the first FDA approval for an immune-stimulatory antibody for MM in this indication.

      Confirming Full-Year 2016 Outlook

      AbbVie is confirming its diluted earnings-per-share guidance of $4.90 to $5.10 on an adjusted basis for the full-year 2016, representing strong double-digit growth versus 2015 and positioning AbbVie to be among the industry leaders for growth again in 2016. The company's 2016 adjusted diluted earnings-per-share guidance excludes $0.45 per share of intangible asset amortization expense and other specified items.  Including these items, AbbVie's diluted earnings-per-share guidance is $4.45 to $4.65 on a GAAP basis.

      About AbbVie

      AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. The call will be webcast through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the call will be available after 11:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2014 and 2015 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2016 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, and competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in item 1A, "Risk Factors," in AbbVie's 2014 Annual Report on Form 10-K and in item 1A, "Risk Factors" of Part II of AbbVie's second quarter 2015 Quarterly Report on Form 10-Q, which have been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


       

      AbbVie Inc.

      Key Product Revenues

      Quarter Ended Dec. 31, 2015

      (Unaudited)




      % Change vs. 4Q14


      Net Revenues (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      ADJUSTED NET REVENUES a

      $3,811 a

      $2,549

      $6,360 a

      23.6% a

      25.4%

      11.4%

      24.4% a

      18.4% a

      Humira

      2,332

      1,385

      3,717

      20.7

      9.7

      (3.4)

      16.0

      10.5

      Imbruvica

      295

      48b

      343

      n/m

      n/m

      n/m

      n/m

      n/m

      Viekira

      197

      357

      554

      n/m

      n/m

      n/m

      n/m

      n/m

      Creon

      185

      --

      185

      22.8

      n/a

      n/a

      22.8

      22.8

      Synagis

      --

      266

      266

      n/a

      (1.2)

      (10.7)

      (1.2)

      (10.7)

      Lupron

      189

      46

      235

      17.9

      7.7

      (1.9)

      15.6

      13.4

      Synthroid

      194

      --

      194

      3.7

      n/a

      n/a

      3.7

      3.7

      Kaletra

      40

      145

      185

      (21.8)

      5.9

      (4.6)

      (1.0)

      (8.9)

      AndroGel

      194

      --

      194

      (15.7)

      n/a

      n/a

      (15.7)

      (15.7)

      Sevoflurane

      22

      86

      108

      1.6

      (0.5)

      (13.2)

      (0.1)

      (10.5)

      Duodopa

      6

      56

      62

      n/m

      14.5

      (0.2)

      24.4

      9.7


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.


      n/a = not applicable

      n/m = not meaningful


      a U.S. and total net revenues in both years exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.

      b Reflects profit sharing for Imbruvica international revenues.

      AbbVie Inc.

      Key Product Revenues

      Twelve Months Ended Dec. 31, 2015

      (Unaudited)




      % Change vs. 12M14


      Net Revenues (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      ADJUSTED NET REVENUES a

      $13,521 a

      $9,298

      $22,819 a

      25.6% a

      17.9%

      2.0%

      22.1% a

      14.8% a

      Humira

      8,405

      5,607

      14,012

      28.8

      8.6

      (6.9)

      19.1

      11.7

      Imbruvica

      659

      95b

      754c

      n/m

      n/m

      n/m

      n/m

      n/m

      Viekira

      804

      835

      1,639

      n/m

      n/m

      n/m

      n/m

      n/m

      Creon

      632

      --

      632

      22.5

      n/a

      n/a

      22.5

      22.5

      Synagis

      --

      740

      740

      n/a

      0.6

      (11.3)

      0.6

      (11.3)

      Lupron

      653

      173

      826

      12.5

      (0.2)

      (12.9)

      9.3

      6.1

      Synthroid

      755

      --

      755

      6.4

      n/a

      n/a

      6.4

      6.4

      Kaletra

      163

      537

      700

      (23.8)

      (4.9)

      (18.2)

      (9.6)

      (19.6)

      AndroGel

      694

      --

      694

      (25.7)

      n/a

      n/a

      (25.7)

      (25.7)

      Sevoflurane

      81

      393

      474

      (2.5)

      (4.0)

      (15.9)

      (3.8)

      (13.9)

      Duodopa

      12

      219

      231

      n/m

      18.1

      (0.6)

      23.5

      4.8


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.


      n/a = not applicable

      n/m = not meaningful


      a U.S. and total net revenues in both years exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.

      b Reflects profit sharing for Imbruvica international revenues.

      c Reflects Imbruvica revenue from the May 26 close date of the Pharmacyclics acquisition.

      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Twelve Months Ended Dec. 31, 2015 and 2014

      (Unaudited) (In millions, except per share data)



      Fourth Quarter
      Ended Dec. 31


      Twelve Months
      Ended Dec. 31



      2015


      2014


      2015


      2014


      Net revenues

      $6,400


      $5,452


      $22,859


      $19,960











      Cost of products sold

      1,475


      1,119


      4,500


      4,426


      Selling, general and administrative

      1,737


      3,341


      6,387


      7,724


      Research and development

      1,075


      879


      4,285


      3,297


      Acquired in-process research and development

      --


      28


      150


      352


      Other expense

      --


      500


      --


      750


      Total operating costs and expenses

      4,287


      5,867


      15,322


      16,549











      Operating earnings (loss)

      2,113


      (415)


      7,537


      3,411











      Interest expense, net

      199


      129


      686


      391


      Net foreign exchange loss

      2


      496


      193


      678


      Other (income) expense, net

      (12)


      (3)


      13


      (27)


      Earnings (loss) before income tax expense

      1,924


      (1,037)


      6,645


      2,369


      Income tax expense (benefit)

      407


      (227)


      1,501


      595


      Net earnings (loss)

      $1,517


      $(810)


      $5,144


      $1,774











      Diluted earnings (loss) per share

      $0.92


      $(0.51)


      $3.13


      $1.10











      Diluted earnings per share, excluding specified items

      $1.13


      $0.89


      $4.29


      $3.32

      a)










      Average diluted shares outstanding     

      1,640


      1,597


      1,637


      1,610



      a) Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended Dec. 31, 2015

      (Unaudited) (In millions, except per share data)


      1.

      Specified items impacted results as follows:





      4Q15




      Earnings

      Diluted




      Pre-tax

      After-tax

      EPS



      As reported (GAAP)

      $1,924

      $1,517

      $0.92



      Adjusted for specified items:






      Other revenue

      (40)

      (25)

      (0.02)



      Intangible asset amortization

      140

      116

      0.07



      Pharmacyclics acquisition related costs

      105

      68

      0.04



      Restructuring

      79

      58

      0.04



      Legal reserves

      125

      101

      0.06



      Separation costs and other      

      43

      26

      0.02



      As adjusted (non-GAAP)

      $2,376

      $1,861

      $1.13





      Other revenue is associated with milestone revenue under a previously announced collaboration. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Pharmacyclics acquisition related costs reflect acquisition-related compensation expense, integration and other costs related to the acquisition of Pharmacyclics. Restructuring is primarily associated with streamlining our global operations. Separation costs and other is primarily related to the separation of AbbVie from Abbott.



      2.

      The impact of the specified items by line item was as follows:





      4Q15



      Net

      Revenues

      Cost of products
      sold

      SG&A

      R&D


       As reported (GAAP)

      $6,400

      $1,475

      $1,737

      $1,075


       Adjusted for specified items:






      Other revenue

      (40)

      --

      --

      --


      Intangible asset amortization

      --

      (140)

      --

      --


      Pharmacyclics acquisition related costs

      --

      (49)

      (15)

      (41)


      Restructuring

      --

      (24)

      (39)

      (16)


      Legal reserves

      --

      --

      (125)

      --


      Separation costs and other

      --

      (16)

      (27)

      --


       As adjusted (non-GAAP)

      $6,360

      $1,246

      $1,531

      $1,018



      3.

      The adjusted tax rate for the fourth quarter of 2015 was 21.6 percent, as detailed below:





      4Q15




      Pre-tax

      Income





      income

      taxes

      Tax rate



      As reported (GAAP)

      $1,924

      $407

      21.1%



      Specified items

      452

      108

      23.9%



      As adjusted (non-GAAP)

      $2,376

      $515

      21.6%


      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended Dec. 31, 2014

      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:




      4Q14








      Earnings

      Diluted








      Pre-tax

      After-tax

      EPS







      As reported (GAAP)

      ($1,037)

      ($810)

      ($0.51)







      Adjusted for specified items:










      Other revenue

      (81)

      (81)

      (0.05)







      Intangible asset amortization

      96

      69

      0.04







      Acquired IPR&D

      28

      29

      0.02







      Calico collaboration

      500

      500

      0.31







      Shire transaction costs      

      2,227

      1,623

      1.00







      Separation costs and other

      134

      116

      0.08







      As adjusted (non-GAAP)

      $1,867

      $1,446

      $0.89










      Other revenue principally includes royalty income from prior periods recognized in the fourth quarter of 2014 as a result of the settlement of a licensing arrangement. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Acquired IPR&D primarily reflects an upfront payment related to a licensing arrangement with a third party. Calico collaboration reflects a charge recorded related to the previously announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Separation costs and other is primarily related to the separation of AbbVie from Abbott.



      2.

      The impact of the specified items by line item was as follows:







      4Q14



      Net

      Revenues

      Cost of
      products

      sold

      SG&A

      R&D

      Acquired
      IPR&D

      Other
      operating
      expense

      Interest
      expense

      Net foreign
      exchange

      loss (gain)


       As reported (GAAP)

      $5,452

      $1,119

      $3,341

      $879

      $28

      $500

      $129

      $496


       Adjusted for specified items:










      Other revenue

      (81)

      --

      --

      --

      --

      --

      --

      --


      Intangible asset amortization

      --

      (96)

      --

      --

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      --

      (28)

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      (500)

      --

      --


      Shire transaction costs

      --

      --

      (1,660)

      --

      --

      --

      (66)

      (501)


      Separation costs and other

      --

      (15)

      (117)

      (2)

      --

      --

      --

      --


       As adjusted (non-GAAP)

      $5,371

      $1,008

      $1,564

      $877

      --

      --

      $63

      ($5)



      3.

      The adjusted tax rate for the fourth quarter of 2014 was 22.5 percent, as detailed below:





      4Q14








      Pre-tax

      Income









      income

      taxes

      Tax rate







      As reported (GAAP)

      ($1,037)

      ($227)

      21.9%







      Specified items

      2,904

      648

      22.3%







      As adjusted (non-GAAP)

      $1,867

      $421

      22.5%






      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended Dec. 31, 2015

      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:





      12M15







      Earnings

      Diluted







      Pre-tax

      After-tax

      EPS






      As reported (GAAP)

      $6,645

      $5,144

      $3.13






      Adjusted for specified items:









      Other revenue

      (40)

      (25)

      (0.02)






      Intangible asset amortization

      419

      328

      0.20






      Separation costs

      270

      223

      0.13






      Pharmacyclics acquisition related costs

      645

      410

      0.25






      Milestones and other R&D expenses

      480

      433

      0.26






      Acquired IPR&D

      150

      150

      0.09






      Shire termination

      170

      170

      0.10






      Restructuring

      113

      82

      0.06






      Legal  reserves

      165

      129

      0.08






      Other      

      23

      16

      0.01






      As adjusted (non-GAAP)

      $9,040

      $7,060

      $4.29








      Other revenue is associated with a milestone payment received under a previously announced collaboration. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Pharmacyclics acquisition related costs reflect acquisition-related compensation expense, transaction, financing, integration and other costs related to the acquisition of Pharmacyclics. Milestones and other R&D expenses are associated with a milestone payment for a previously announced collaboration and the purchase of an FDA priority review voucher from a third party. Acquired IPR&D primarily reflects the C2N collaboration. Shire termination reflects the completed liquidation of remaining foreign currency positions related to the terminated Shire transaction, as communicated in the fourth quarter of 2014. Restructuring is primarily associated with streamlining our global operations.



      2.

      The impact of the specified items by line item was as follows:





      12M15



      Net
      Revenues

      Cost of
      products
      sold

      SG&A

       

      R&D

      Acquired
      IPR&D

      Interest

      expense

      Net foreign
      exchange

      loss


       As reported (GAAP)

      $22,859

      $4,500

      $6,387

      $4,285

      $150

      $686

      $193


       Adjusted for specified items:









      Other revenue

      (40)

      --

      --

      --

      --

      --

      --


      Intangible asset amortization

      --

      (419)

      --

      --

      --

      --

      --


      Separation costs

      --

      (5)

      (265)

      --

      --

      --

      --


      Pharmacyclics acquisition related costs

      --

      (113)

      (294)

      (152)

      --

      (86)

      --


      Milestones and other R&D expenses

      --

      --

      --

      (480)

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      --

      (150)

      --

      --


      Shire termination

      --

      --

      --

      --

      --

      --

      (170)


      Restructuring

      --

      (42)

      (39)

      (32)

      --

      --

      --


      Legal reserves

      --

      --

      (165)

      --

      --

      --

      --


      Other

      --

      (16)

      (3)

      (4)

      --

      --

      --


       As adjusted (non-GAAP)

      $22,819

      $3,905

      $5,621

      $3,617

      --

      $600

      $23



      3.

      The adjusted tax rate for the full-year 2015 was 21.9 percent, as detailed below:





      12M15







      Pre-tax

      Income








      income

      taxes

      Tax rate






      As reported (GAAP)

      $6,645

      $1,501

      22.6%






      Specified items

      2,395

      479

      20.0%






      As adjusted (non-GAAP)

      $9,040

      $1,980

      21.9%





      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended Dec. 31, 2014

      (Unaudited) (In millions, except per share data)




      1.

      Specified items impacted results as follows:







      12M14









      Earnings

      Diluted









      Pre-tax

      After-tax

      EPS








      As reported (GAAP)

      $2,369

      $1,774

      $1.10








      Adjusted for specified items:











      Other revenue

      (81)

      (81)

      (0.05)








      Intangible asset amortization

      403

      287

      0.18








      Separation costs

      445

      385

      0.24








      Milestones and other R&D expenses

      40

      40

      0.02








      Acquired IPR&D

      352

      251

      0.15








      Calico collaboration

      750

      750

      0.46








      Shire transaction costs

      2,510

      1,802

      1.12








      Other

      136

      167

      0.10








      As adjusted (non-GAAP)

      $6,924

      $5,375

      $3.32











      Other revenue principally includes royalty income from prior periods recognized in the fourth quarter of 2014 as a result of the settlement of a licensing arrangement. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Milestones and other R&D expenses are associated with payments for previously announced collaborations. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Calico collaboration reflects charges related to the previously announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Other is primarily associated with the recognition of an additional year of the Branded Prescription Drug Fee as required by new IRS regulations.




      2.

      The impact of the specified items by line item was as follows:








      12M14



      Net

      Revenues

      Cost of
      products
      sold

      SG&A

      R&D

      Acquired
      IPR&D

      Other
      operating
      expense

      Net foreign
      exchange
      loss

      Interest
      expense

      Other
      (income)
      expense


       As reported (GAAP)

      $19,960

      $4,426

      $7,724

      $3,297

      $352

      $750

      $678

      $391

      ($27)


       Adjusted for specified items:











      Other revenue

      (81)

      --

      --

      --

      --

      --

      --

      --

      --


      Intangible asset amortization

      --

      (403)

      --

      --

      --

      --

      --

      --

      --


      Separation costs

      --

      (18)

      (422)

      (5)

      --

      --

      --

      --

      --


      Milestones and other R&D expenses

      --

      --

      --

      (40)

      --

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      --

      (352)

      --

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      (750)

      --

      --

      --


      Shire transaction costs

      --

      --

      (1,703)

      --

      --

      --

      (666)

      (141)

      --


      Other

      --

      (58)

      (112)

      --

      --

      --

      --

      --

      34


       As adjusted (non-GAAP)

      $19,879

      $3,947

      $5,487

      $3,252

      --

      --

      $12

      $250

      $7



      3.

      The adjusted tax rate for the full-year 2014 was 22.4 percent, as detailed below:





      12M14








      Pre-tax

      Income









      income

      taxes

      Tax rate







      As reported (GAAP)

      $2,369

      $595

      25.1%







      Specified items

      4,555

      954

      20.9%







      As adjusted (non-GAAP)

      $6,924

      $1,549

      22.4%






      SOURCE AbbVie

      Modal title

      Also from this source

      Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic...

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.